Provided by Tiger Trade Technology Pte. Ltd.

Imunon, Inc.

1.32
+0.03002.33%
Pre-market: 1.340.0200+1.52%08:32 EDT
Volume:138.01K
Turnover:180.10K
Market Cap:7.41M
PE:-0.37
High:1.39
Open:1.29
Low:1.26
Close:1.29
52wk High:5.55
52wk Low:1.26
Shares:5.61M
Float Shares:5.28M
Volume Ratio:1.03
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5719
EPS(LYR):-6.8265
ROE:-429.72%
ROA:-77.99%
PB:3.82
PE(LYR):-0.19

Loading ...

Imunon Announces Press Release Available

Reuters
·
Jul 23

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

GlobeNewswire
·
Jul 23

Imunon General Counsel Susan Eylward Disposes of 2,150 Common Shares Worth $3,830.44

Reuters
·
Jul 22

Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response

MT Newswires Live
·
Jul 21

Imunon announces new preliminary data from IMNN-001 trial

TIPRANKS
·
Jul 21

Imunon - Imnn-001 Under Evaluation in Phase 3 Ovation 3 Trial for Advanced Ovarian Cancer

THOMSON REUTERS
·
Jul 21

Imunon Reports Positive Phase 2 Mrd Clinical Data for Imnn-001, Demonstrating the Successful Overcoming of Historical Il-12 Safety Barriers in Frontline Ovarian Cancer

THOMSON REUTERS
·
Jul 21

Imunon - no Cytokine Release Syndrome or Serious Immune-related Adverse Events Observed with Imnn-001

THOMSON REUTERS
·
Jul 21

Imunon - Imnn-001 Demonstrates Lower Mrd Rate, Higher Ctdna Clearance, and Higher Ned Rate vs Control

THOMSON REUTERS
·
Jul 21

Imunon - Imnn-001 Shows Highly Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Jul 21

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

GlobeNewswire
·
Jul 21

Imunon Files Form 3 for CFO Joshua Blacher

Reuters
·
Jul 08

Imunon General Counsel Susan Eylward Disposes of 920 Common Shares Worth $1,729.6

Reuters
·
Jul 08

Imunon interim CFO Jeffrey Church to retire, Josh Blacher to succeed

TIPRANKS
·
Jul 01

Imunon - Jeffrey Church to Retire as Interim CFO Effective July 1, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

Imunon Names Josh Blacher Interim CFO Effective July 1

Reuters
·
Jul 01

Imunon General Counsel Susan Eylward Sells 11,800 Common Shares for $20,674.8

Reuters
·
Jun 30

Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue

MT Newswires Live
·
Jun 23

Imunon announces IDMC recommendation for continuation of OVATION 3 trial

TIPRANKS
·
Jun 23

IMUNON says data monitoring committee backs continuing Phase 3 OVATION 3 ovarian cancer trial unchanged

Reuters
·
Jun 23